Durect Corporation (DRRX) - Total Liabilities

Latest as of June 2025: $8.54 Million USD

Based on the latest financial reports, Durect Corporation (DRRX) has total liabilities worth $8.54 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore DRRX operating cash flow to assess how effectively this company generates cash.

Durect Corporation - Total Liabilities Trend (1999–2024)

This chart illustrates how Durect Corporation's total liabilities have evolved over time, based on quarterly financial data. Check Durect Corporation (DRRX) asset resilience to evaluate the company's liquid asset resilience ratio.

Durect Corporation Competitors by Total Liabilities

The table below lists competitors of Durect Corporation ranked by their total liabilities.

Company Country Total Liabilities
Inta Bina Group Bhd
KLSE:0192
Malaysia RM431.27 Million
Equus Energy Ltd
AU:EQU
Australia AU$159.97K
Everspring Industry Co Ltd
TW:2390
Taiwan NT$328.19 Million
Amiad Water Systems Ltd
TA:AMD
Israel ILA71.22 Million
Alliance Witan Ord
LSE:ALW
UK GBX402.29 Million
Global Mofy Metaverse Limited Ordinary Shares
NASDAQ:GMM
USA $16.07 Million
Cepatwawasan Group Bhd
KLSE:8982
Malaysia RM87.74 Million
Manba Finance Ltd
NSE:MANBA
India Rs14.99 Billion

Liability Composition Analysis (1999–2024)

This chart breaks down Durect Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Durect Corporation (DRRX) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.98 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 2.17 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.68 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Durect Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Durect Corporation (1999–2024)

The table below shows the annual total liabilities of Durect Corporation from 1999 to 2024.

Year Total Liabilities Change
2024-12-31 $9.22 Million -69.68%
2023-12-31 $30.41 Million -13.41%
2022-12-31 $35.12 Million +2.65%
2021-12-31 $34.21 Million -3.71%
2020-12-31 $35.53 Million -43.75%
2019-12-31 $63.16 Million +110.54%
2018-12-31 $30.00 Million -5.14%
2017-12-31 $31.62 Million -1.69%
2016-12-31 $32.17 Million +0.88%
2015-12-31 $31.89 Million +1.01%
2014-12-31 $31.57 Million +212.60%
2013-12-31 $10.10 Million +5.15%
2012-12-31 $9.60 Million -78.99%
2011-12-31 $45.72 Million -13.86%
2010-12-31 $53.07 Million +72.68%
2009-12-31 $30.73 Million -20.08%
2008-12-31 $38.45 Million -22.22%
2007-12-31 $49.44 Million -24.47%
2006-12-31 $65.45 Million -11.62%
2005-12-31 $74.06 Million +10.41%
2004-12-31 $67.08 Million -0.32%
2003-12-31 $67.29 Million +891.19%
2002-12-31 $6.79 Million -14.01%
2001-12-31 $7.89 Million +47.35%
2000-12-31 $5.36 Million +208.82%
1999-12-31 $1.74 Million --

About Durect Corporation

NASDAQ:DRRX USA Drug Manufacturers - Specialty & Generic
Market Cap
$59.31 Million
Market Cap Rank
#21234 Global
#4537 in USA
Share Price
$1.91
Change (1 day)
-1.04%
52-Week Range
$0.50 - $1.96
All Time High
$38.00
About

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment… Read more